# Crescendo Biologics announces publication of data for CB213, a PD-1xLAG-3 multi-specific Humabody®, in the *British Journal of Cancer*

- Data show potent action of CB213 mediated by simultaneous blockade of both PD-1 and LAG-3 checkpoint targets
- CB213 induces significant T cell proliferation, and data illustrate evidence of direct and significant anti-tumour activity in preclinical models

**Cambridge, UK, 31 December 2021** – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that new data have been published in the *British Journal of Cancer* on the preclinical pharmacology of CB213, Crescendo's fully human PD-1xLAG-3 co-targeting multi-specific Humabody®.

CB213 is a novel therapeutic candidate and is composed of linked $V_H$ domains that avidly bind and block PD-1 and LAG-3 on dual-positive T cells. It was discovered using Crescendo's proprietary transgenic mouse platform, which generates fully human $V_H$ domain building blocks (Humabody® $V_H$). CB213 was developed to preferentially target T cells expressing both PD-1 and LAG-3, as opposed to T cells expressing only PD-1. It is anticipated that this approach could confer a clinical safety advantage whilst maintaining or improving efficacy. CB213 is designed as a LAG-3xLAG-3xPD-1 triple $V_H$ construct with the addition of a human serum albumin binding fragment for prolonged pharmacokinetic exposure and to promote a greater degree of accumulation in tumour tissue.

The pharmacology data published for CB213 illustrate its potent action, mediated by simultaneous blockade of the PD-1 and LAG-3 checkpoint targets. The data also highlight the ability of CB213 to induce significant T cell proliferation in peripheral blood obtained from patients with non-small cell lung cancer as well as evidence of its direct and significant anti-tumour activity in preclinical models.

These data have been published in the *British Journal of Cancer;* the full paper by Edwards *et al* can be accessed online HERE.

"We are very pleased that these CB213 preclinical data have been published in such a prestigious medical journal. They not only showcase the elegant pharmacology of this novel molecule but also add to the expanding body of knowledge of the potential of Humabodies to address significant unmet medical needs," commented **Dr Philip Bland-Ward, Chief Development Officer at Crescendo**. "Recent clinical data from combination studies with monospecific molecules have highlighted the potential therapeutic benefits from dual-targeting of PD-1 and LAG-3. Given the compelling preclinical data for CB213 we are looking forward to moving this exciting new therapeutic towards the clinic."

In April 2020, Crescendo signed a clinical development partnership with Cancer Research UK to progress CB213 into clinical trials targeting cancers of high unmet medical need. Under the terms of the

agreement, Cancer Research UK's Centre for Drug Development will sponsor and fund a Phase I clinical trial for CB213 in patients with solid tumours. Crescendo retains the right to further develop CB213 by licensing the results of the trial from Cancer Research UK.

-Ends-

**For more information, please contact:**


**Crescendo Biologics**

Michael Booth, CFO
+ 44 (0)1223 497140
investors@crescendobiologics.com
media@crescendobiologics.com

**Instinctif Partners**

Melanie Toyne-Sewell, Katie Duffell, Nathan Billis
+ 44 (0)20 7457 2020
crescendo@instinctif.com


**About Crescendo Biologics**

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody® for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours.

The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human $V_H$ domain building blocks (Humabody® $V_H$). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Beyond Crescendo's proprietary pipeline, the Company has a global, multi-target discovery and development collaboration with Takeda; a clinical development partnership for CB213 (a PD-1xLAG-3 multi-specific Humabody®) with Cancer Research UK; and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody®), which has recently successfully completed a Phase 1 clinical trial.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit www.crescendobiologics.com and follow @HUMABODY.